Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Marta Palafox"'
Autor:
María Jimena Rodriguez, María Cecilia Perrone, Marina Riggio, Marta Palafox, Valeria Salinas, Andrés Elia, Natali Daiana Salgueiro, Andrea Eugenia Werbach, María Paula Marks, Marcelo A. Kauffman, Luciano Vellón, Violeta Serra, Virginia Novaro
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel th
Externí odkaz:
https://doaj.org/article/894327144ae548bf939fc2408e72085d
Autor:
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Externí odkaz:
https://doaj.org/article/c3a330e420d34dc992aab0ec2b80986a
Autor:
Lidia Mateo, Miquel Duran-Frigola, Albert Gris-Oliver, Marta Palafox, Maurizio Scaltriti, Pedram Razavi, Sarat Chandarlapaty, Joaquin Arribas, Meritxell Bellet, Violeta Serra, Patrick Aloy
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-23 (2020)
Abstract Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) network
Externí odkaz:
https://doaj.org/article/8d63f66e5204442188fe04baf4456244
Autor:
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/c47a0b935486445aafab933f5d652620
Autor:
Marinela Méndez-Pertuz, Paula Martínez, Carmen Blanco-Aparicio, Elena Gómez-Casero, Ana Belen García, Jorge Martínez-Torrecuadrada, Marta Palafox, Javier Cortés, Violeta Serra, Joaquin Pastor, Maria A. Blasco
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-17 (2017)
Regulation of telomeres and the insulin/PI3K pathway both have roles in aging and cancer development but have not been functionally linked. Here the authors demonstrate that PI3K, via downstream targets, regulates TRF1 via phosphorylation.
Externí odkaz:
https://doaj.org/article/2d614c1112c2497aaf67ea663b43f2d5
Autor:
Jorge Gómez-Miragaya, Marta Palafox, Laia Paré, Guillermo Yoldi, Irene Ferrer, Sergi Vila, Patricia Galván, Pasquale Pellegrini, Hector Pérez-Montoyo, Ana Igea, Purificación Muñoz, Manel Esteller, Angel R. Nebreda, Ander Urruticoechea, Idoia Morilla, Sonia Pernas, Fina Climent, María Teresa Soler-Monso, Ana Petit, Violeta Serra, Aleix Prat, Eva González-Suárez
Publikováno v:
Stem Cell Reports, Vol 8, Iss 5, Pp 1392-1407 (2017)
Taxanes are a mainstay of treatment for breast cancer, but resistance often develops followed by metastatic disease and mortality. Aiming to reveal the mechanisms underlying taxane resistance, we used breast cancer patient-derived orthoxenografts (PD
Externí odkaz:
https://doaj.org/article/4f17da8dcc6a4c1abea0af3c702c89e0
Autor:
Adriana Blancafort, Ariadna Giró-Perafita, Glòria Oliveras, Sònia Palomeras, Carlos Turrado, Òscar Campuzano, Dolors Carrión-Salip, Anna Massaguer, Ramon Brugada, Marta Palafox, Jorge Gómez-Miragaya, Eva González-Suárez, Teresa Puig
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0131241 (2015)
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma cells. The hypothesis is that blocking FASN, in combination with anti-HER2 signaling agents, would be an effective antitumor strategy in preclinical H
Externí odkaz:
https://doaj.org/article/d0946f7276224e738d25e57de6ec46aa
Autor:
Milica Vulin, Charly Jehanno, Atul Sethi, Ana Luísa Correia, Milan M. S. Obradović, Joana Pinto Couto, Marie-May Coissieux, Maren Diepenbruck, Bogdan-Tiberius Preca, Katrin Volkmann, Priska Auf der Maur, Alexander Schmidt, Simone Münst, Loïc Sauteur, Michal Kloc, Marta Palafox, Adrian Britschgi, Vincent Unterreiner, Olaf Galuba, Isabelle Claerr, Sandra Lopez-Romero, Giorgio G. Galli, Daniel Baeschlin, Ryoko Okamoto, Savas D. Soysal, Robert Mechera, Walter P. Weber, Thomas Radimerski, Mohamed Bentires-Alj
Publikováno v:
Oncogene. 41:4459-4473
Plasticity delineates cancer subtypes with more or less favourable outcomes. In breast cancer, the subtype triple-negative lacks expression of major differentiation markers, e.g., estrogen receptor α (ERα), and its high cellular plasticity results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d63aa2dd9501f2424f301e979d8bdcf8
https://doi.org/10.1038/s41388-022-02429-0
https://doi.org/10.1038/s41388-022-02429-0
Autor:
Sarat Chandarlapaty, Nathanael S. Gray, John D. Chodera, Andrew Koff, Violeta Serra, Neal Rosen, Eric S. Fischer, Elisa de Stanchina, Jorge S. Reis-Filho, Marta Palafox, Katherine A. Donovan, Jennifer A. Roth, Melissa M. Ronan, Matthew G. Rees, Andrew S. Boghossian, Bo Liu, Pedram Razavi, Zhiqiang Li, Rei Kudo, Qing Chang, Isabella S. Del Priore, Hong Shao, Jiaye Guo, Baishan Jiang, Qing Li
Supplementary Figure from INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c59cbf947e2a4583d8ecb009dacb67
https://doi.org/10.1158/2159-8290.22540567
https://doi.org/10.1158/2159-8290.22540567
Autor:
Sarat Chandarlapaty, Nathanael S. Gray, John D. Chodera, Andrew Koff, Violeta Serra, Neal Rosen, Eric S. Fischer, Elisa de Stanchina, Jorge S. Reis-Filho, Marta Palafox, Katherine A. Donovan, Jennifer A. Roth, Melissa M. Ronan, Matthew G. Rees, Andrew S. Boghossian, Bo Liu, Pedram Razavi, Zhiqiang Li, Rei Kudo, Qing Chang, Isabella S. Del Priore, Hong Shao, Jiaye Guo, Baishan Jiang, Qing Li
Cyclin-dependent kinases 4 and 6 (CDK4/6) represent a major therapeutic vulnerability for breast cancer. The kinases are clinically targeted via ATP competitive inhibitors (CDK4/6i); however, drug resistance commonly emerges over time. To understand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27eddefc54f2bcf3adf0f3f3b7b424c0
https://doi.org/10.1158/2159-8290.c.6549415
https://doi.org/10.1158/2159-8290.c.6549415